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Oligopeptide derivatives of metenkephalin were found to stimulate growth-hormone (GH) release directly by pituitary
somatotrope cells in vitro in 1977. Members of this class of peptides and nonpeptidyl mimetics are referred to as GH
secretagogues (GHSs). A speciﬁc guanosine triphosphatate-binding protein-associated heptahelical transmembrane receptor
for GHS was cloned in 1996. An endogenous ligand for the GHS receptor, acylghrelin, was identiﬁed in 1999. Expression
of ghrelin and homonymous receptor occurs in the brain, pituitary gland, stomach, endothelium/vascular smooth muscle,
pancreas, placenta, intestine, heart, bone, and other tissues. Principal actions of this peptidergic system include stimulation of
GH release via combined hypothalamopituitary mechanisms, orexigenesis (appetitive enhancement), insulinostasis (inhibition
of insulin secretion), cardiovascular eﬀects (decreased mean arterial pressure and vasodilation), stimulation of gastric motility
and acid secretion, adipogenesis with repression of fat oxidation, and antiapoptosis (antagonism of endothelial, neuronal, and
cardiomyocyte death). The array of known and proposed interactions of ghrelin with key metabolic signals makes ghrelin and its
receptor prime targets for drug development.
1. Overview
Fundamental questions in peptide biology are the extent
to which any given peptide operates in isolation versus
interdependently, locally or systemically, and via a single
pleiotropic or multiple distinct receptors. Identiﬁcation
of the ghrelin/GHS family initially disclosed GH-releasing
properties [1]. Investigations subsequently unveiled multior-
gan expression [2–4], multivariate actions [5], and complex
modulation of and by collateral eﬀectors [1, 4]: Table 1.
The burgeoning repertoire of ghrelin actions mimics that
of inhibin and activin [6, 7], which were originally iso-
lated as regulators of follicle-stimulating hormone secretion,
and thereafter recognized for hematopoietic and oncologic
activity. Analogously, prominent clinical applications of
ghrelin/GHS may involve not only GH-stimulating eﬀects
but also appetitive, metabolic, cardiovascular, locomotive,
and gastrointestinal signaling: Figure 1. Recent development
of transgenic mice expressing ghrelin-eGFP (enhanced green
ﬂuorescent protein) should permit more detailed mapping
of ghrelin-expressing neurons in hypothalamic arcuate and
ventromedial nuclei [8–10] and ghrelin-expressing cells in
gastric oxyntic glands, pancreatic islets (epsilon cells), the
anterior pituitary gland, bone marrow, and other less well-
studied sites [4, 11, 12].
2. Unique Facets of Ghrelin
2.1. Multiplicity of Roles. The etymology of ghrelin is “ghre”
for “growth”, consonant with the report by Bowers et al.
of direct pituitary GH-releasing eﬀects of metenkephalin-
derived synthetic oligopeptides three decades ago [1].
The peptides were initially termed GH-releasing peptides
(GHRPs), and more recently GH secretagogues (GHSs) to
include congeneric molecules [2]. Multiple peptidyl and
several nonpeptidyl analogs of ghrelin (GHS) have been
developed and assessed functionally over the last three
decades. The ghrelin receptor was cloned in 1996 by Howard2 International Journal of Peptides
Table 1: Interactions with ghrelin.
(a) Regulation of ghrelin gene
Stimulation Repression
(1) GHRH (pituitary) (1) Leptin (hypothalamus)
(2) Octanoate (stomach) (2) Glucagon-like peptide (hypothalamus)
(3) Estradiol (stomach) (3) Peptide YY (3-36) (hypothalamus)
(4) Glucagon (rat stomach) (4) Insulin (stomach)
(5) Cholecystokinin (stomach) (5) Somatostatin (pituitary, stomach)
(6) Hypoglycemia (stomach) (6) Histamine (stomach)
(7) Acetylcholine (stomach) (7) Hypoglycemia (brain)
(8) Leptin (stomach) (8) Glucagon∗
(b) Regulation of ghrelin receptor
Activation Suppression
(1) Constitutive expression (1) Estradiol (appetitive eﬀects)
(2) Acylghrelin (2) GH (hypothalamus and pituitary)
(3) Estradiol (in vitro) (3) IGF-I (pituitary)
(c) Modulation of ghrelin action
Potentiation Inhibition
(1) GHRH (GH release) (1) Testosterone (dog and rat)
(2) Estradiol (GH release) (2) Free Fatty acids (pituitary)
(3) L-arginine (GH release) (3) Leptin (neurons)
(3) Desacyl-ghrelin (hunger, insulinostasis)
(d) Mediation of ghrelin actions
Appetitive Cardiovascular
(1) NPY (↑) (1) Nitric oxide (↑)
(2) Orexin A (↑) (2) Extracellular-receptor activated kinases (↑)
(3) Leptin (↓) (3) Unknown desacyl-ghrelin receptor
(4) Insulin (↓) (4) CD36 (type B scavenger receptor)
Stomach Pituitary
(1) GHS receptor-1a (1) Phospholipase C
(2) ? CRH receptor-2 (2) Diacylglycerol
(3) Protein-kinase C
(4) Ca2+ signals
Pancreas
(1) Inward Ca2+ and outward K+ channels
(e) Regulation of ghrelin octanoyl-acyl transferase (GOAT)
Stimulation Inhibition
(1) Long-term fasting (stomach) (1) By acylghrelin (stomach)
(2) Acetylcholine
(3) Leptin
∗ IV glucagon suppresses serum ghrelin concentrations in humans [121].
Selected References: [9, 15, 52, 88, 122–127].
et al. based upon phospholipase C-mediated intracellular
inositol triphosphatate-dependent Ca2+ signal generation
in transfected cells [5]. In certain systems, such as pitu-
itary somatotropes, gastric oxyntic cells, appetitive neurons,
pancreatic islets, and endothelial cells, additional messen-
gers like phosphoinositidyl-3-kinase, Akt/protein kinase B,
adenosine monophosphate protein kinase (AMP kinase),
and nitric oxide may modulate ghrelin’s actions [13–20]:
Table 1. Mitogen-activated protein kinases (MAPKs) and
extracellularly regulated kinases (ERKs 1/2) may mediate
certain of ghrelin’s proliferative and antiapoptic eﬀects [15,
21, 22].
2.2. GH-Releasing Mechanisms. Ghrelin and cognate recep-
tor, GHS-R1a, are distinct entirely from GH-releasing hor-
mone, GHRH, and its receptor isolated in 1982 by the
Guillemain and Vale laboratories from human pancreatic
neoplasms [23, 24]. The homotypic GHRH receptor is an
adenylyl cyclase-activating seven transmembrane-spanningInternational Journal of Peptides 3
Preproghrelin
Desacyl ghrelin
Acylghrelin
obestain {↓ Apoptosis, ↑ diﬀerentiation}
Esterases GOAT
{↑ Growth hormone, ↓ locomotion, ↑ appetite}
C-terminal fragments
Plus
{↓ Thirst, ↑ urocortin-2}
Three peptides generated from preproghrelin
(a)
CNS
Pituitary
Ghrelin
deacylase Blood
ghrelin
Cardiovascular
Beta cells
Fat cells
Stomach
Vagus
nerve
Stomach
Duodenum
• Ghrelin octanoyl-acyltransferase (GOAT)
• Ghrelin deacylase(s)
• Motility
• Acid secretion
↑ GH release
↑ Appetite
↑ ACTH, prolactin
↓ Locomotion
↑ Adipogenesis
↓ Energy expenditure
Appetite, gastric
motility and
acidity
↑
Principal actions and origins of ghrelin
(b)
Figure 1: Principal peptide products of preproghrelin (a) and primary actions of ghrelin recognized to date (b) (unpublished line drawing).
GTP-binding protein [25]. GHRH neurons in the arcuate
nucleus express GHS-R1a, but hypothalamic ghrelin neu-
rons do not manifest GHRH receptors [4]. Both neuronal
ensembles are extensive and project to the external layer of
the pituitary stalk [11]. Nonetheless, to date, any direct role
for hypothalamic release of ghrelin to the pituitary gland
remains undocumented [26]. Ghrelin is unusual in that
existence of the receptor was predicted three decades and
clonedthreeyears,beforethenaturalligandwasidentiﬁedby
Kojima et al. in 1999 [3]. The ghrelin receptor exhibits high
basal activity even unstimulated. Mutational disruption of
constitutiveGHS-R1aactivityisassociatedwithshortstature
in humans [27], whereas overexpression of GHS-R1a on
GHRH neurons augments postweaning growth, reduces fat
mass, and augments GHRH and GH gene expression in mice
[28]. Thus, GHS-R1a is an ampliﬁer of GHRH outﬂow as
well as a direct eﬀector of pituitary GH secretion. Exogenous
GHS partially overcomes GH inhibition by glucose and
infused somatostatin [29, 30]. Neurophysiological data and
immediate-earlygeneresponseshaverevealedtwoadditional
mechanisms of ghrelin action, namely, partial antagonism
of noncompetitive hypothalamic and pituitary inhibition
by somatostatin and of hypothalamic melanocortin and
leptin pathways [31–40]. Figure 2 depicts a model, which
incorporates several major actions of ghrelin/GHS within
the GH axis [41]. This model does not include pituitary
ghrelin, which is downregulated by excessive thyroxine,
glucocorticoid, or brain-GH feedback and upregulated by
GHRH [42]. Selective silencing of the pituitary ghrelin gene
will be required to discern its physiological role.
2.3.StructuralFeatures. Ghrelinisuniqueastheﬁrstacylated
peptide recognized in mammals requiring a short-chain
fatty-acid (octanoyl, decanoyl, or decenoyl) moiety linked
to the third N-terminal amino acid (usually serine) for
primary biological activity, namely. GHRH and GH release,
locomotor suppression and appetite stimulation [26, 43–
45]. Decanoyl and octanoyl moieties seem equipotent.
The enzyme mediating Ser3 acylation was cloned by the4 International Journal of Peptides
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Figure 2: Model-based functional networks subserving GH secretion, showing major eﬀects of GH-releasing hormone (GHRH) and
somatostatin (SS) as modiﬁed by GHS (ghrelin). D1 and D2 denote time delays. ArC and PeV deﬁne arcuate and periventricular nuclei
(adapted from [41]).
Brown and Goldstein laboratory in 2008 and named ghrelin
octanoyl-acyltransferase (GOAT) [46–48]. GOAT is one
of 16 members of membrane-bound O-acyltransferases
[49]. It is expressed in pancreas, stomach, skeletal muscle,
heart, intestine, bone, and other organs and is endprod-
uct inhibited and fatty-acyl substrate and fasting induced
[50–52]. GOAT protein and transcripts exist in individ-
ual ghrelin-containing gastric mucosal oxyntic cells [53].
Regulation may exist pretranslationally also, since natural
antisense ghrelin RNA’s can be demonstrated by analysis of
human genomic DNA [54, 55]. A second acyltransferase,
termed microsomal zinc-stimulated serine (Ser2 ghrelin)
octanoyltransferase, distinct from GOAT, was cloned by
Ozawa et al. in 2009 [56]. This enzyme is concentrated
in the endoplasmic reticulum of human erythroleukemia
cells. Its in vivo role is not yet known but might include
negative regulation of GOAT via the octanoylated products
generated.
Unacylated ghrelin competes with acylghrelin for GHS-
R1a to a negligible degree, namely, with a kd of 13μM,
which is four orders of magnitude greater than that for
bioactive peptide [57]. Deacylases (esterases) of ghrelin exist
in the blood and stomach, which may be nonselective
[58, 59]. GOAT can utilize both ghrelin (1–4) and ghrelin
(1–5) as substrates for serine acylation, consistent with
their core structure [46, 60]. Des-Gln acylghrelin (1–27),
an alternative transcript lacking glutamine in N-terminal
position 14, is also fully active on the GHS-R1a receptor
[61]. Ghrelin’s amino-acid sequence is signiﬁcantly con-
served in ﬁsh, reptiles, amphibia, birds, and mammals [62].
Congeneric molecules include GHRP-2, GHRP-6, hexarelin,
ipamorelin, ibutamorelin, and the nonpeptide MK-0677,
which like ghrelin rapidly induce inositol triphosphate,
diacylglycerol, and Ca2+ release via the GHS-R1a [51, 63–
67].
2.4. Blood-Borne Ghrelin. Ghrelin concentrations in blood
comprise principally desacyl-ghrelin (85%–90%) and in
lesser amounts acylghrelin (10%–15%) and C-terminal
proghrelin peptides [68, 69]. In large cohorts, ghrelin is
higher in women than men [70] and declines with age,
body mass index (BMI), hypertension, and other markers
of the metabolic syndrome [70]. The inverse relationships
between ghrelin and both BMI and insulin concentrations
appear to explain much of the age eﬀect [71]. Appropriate
sample collection and storage are necessary to limit ghrelin
deacylation before assay [72, 73]. Although its exact role is
not known, desacyl-ghrelin can exert a variety of agonistic
and antagonistic actions [74–76], as discussed further in
the relation to the ghrelin receptor. Octanoylated and total
ghrelin levels in the stomach and blood rise between meals,
during fasting, in cachexia, anorexia, or malnutrition, type
I (insulinopenic) diabetes mellitus, after acute endotoxin
exposure, overnight during initial deep sleep and in response
to estradiol (E2), acute hypoglycemia, glucagon infusion,
vagal stimulation, and chronic octanoate ingestion [77–89]:
Figure 3. In mice, plasma bioactive decanoylated ghrelin
increases and octanoylated ghrelin paradoxically decreases
during fasting [90], suggesting precise posttranslational
control [72]. Unlike gastric ghrelin, hypothalamic ghrelin
gene transcript and peptide levels fall during short-term
fasting [9].
In various studies, serum total ghrelin concentrations
correlate positively with E2, IGFBP-1, and creatinine concen-
trations, and negatively with somatostatin, insulin, thyrox-
ine, leptin, and testosterone (T) concentrations and arterial
blood pressure [70, 82, 86, 91–98]. Thus, ghrelin levels rise
notonlyinfastingindividualsbutalsoinestrogen/progestin-
treated women [99–101], combined antiandrogen and
progestin-treated men [82], and the estrogen-rich milieu of
the late follicular phase of the menstrual cycle in one butInternational Journal of Peptides 5
Gastric ghrelin regulation
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Figure 3: Key hormonal, gastrointestinal, nutritional, stress-related, infectious, and physiological regulators of gastric ghrelin secretion
inferred in mammalian species.
not another study [92, 102]. Conversely, ghrelin levels fall
in the high-testosterone milieu of male puberty [93]. Gastric
ghrelin-secreting cells express estrogen receptor-alpha [103],
thus potentially mediating some sex-steroid eﬀects. Indeed,
gonadal downregulation in girls and parenteral (but not
transdermal) testosterone administration in boys diminish
plasma ghrelin concentrations [104, 105]. In addition, clini-
cal investigations indicate that E2 or T supplementation can
potentiate GH secretion stimulated by a ﬁxed submaximal
doseofGHS/ghrelin[106–112].Ontheotherhand,low-dose
transdermal E2 administration did not augment maximal
GH stimulation by ghrelin in postmenopausal women [113],
and the potentiating action of T administration on GHS was
not evident in the dog, rat, or older men [114, 115]. Thus,
more data are needed on the developmental dependence
of sex-steroidal facilitation of GHS action. The diﬀerences
before and after puberty do not seem to be due to feedback
by diﬀering GH levels, since acute infusion of GH or a GH-
receptor antagonist does not feed back onto ghrelin secretion
[116, 117]. Chronic GH excess or deﬁciency and exercise also
do not consistently modify ghrelin production in humans or
animals [118–120].
Food intake, especially amino acids, glucose but not
fructose, dodecanoate, and other long-chain fatty acids,
T administration, euglycemic hyperinsulinemia, impaired
glucose tolerance, infusion of free fatty acids, somatostatin,
cortistatin or urocortin, obesity (elevated body-mass index
and increased total, subcutaneous or visceral fat), weight
gain, hyperthyroidism, and leptin injection suppress ghrelin
concentrations [86, 97, 116, 117, 128–144]. A possible intra-
cellular mediator of fasting and feeding’s reciprocal control
of ghrelin secretion is the mammalian target of rapamycin
[145], which is suppressed by fasting [145]. In general, total
ghrelin concentrations nearly double before meals and fall
to a nadir about one hour thereafter [146]. Protein (more
than lipid) ingestion strongly suppresses plasma acylghrelin,
whereas carbohydrate initially suppresses and then elevates
circulating ghrelin in humans [147]. Gastrectomy reduces
total ghrelin concentrations by 65%–80% (to 20%–35% of
baseline) [148], thereby verifying that the stomach is the
major source of this hormone.
Acylated ghrelin typically changes in parallel with total
ghrelin availability and in the fed state may rise recurrently
before GH pulses [149]. Dissociations between acyl and
desacyl-ghrelin levels occur after ﬁber versus total energy
intake [150], intravenous glucose infusion [142], in renal
failure [86], and in the portal vis-` a-vis hepatic veins because
of preferential liver extraction of the acylated moiety [142].
In clinical studies, meal-induced depression of ghrelin
levels may be attenuated in children compared with adults,
and in women with polycystic ovarian syndrome (PCOS)
compared with healthy women, but accentuated in African-
American compared with Caucasian women [151–154]. The
antiandrogen, ﬂutamide, increased ghrelin levels in patients
withPCOS,suggestingsuppressionofghrelinproductionvia
the androgen receptor in this hyperandrogenemic syndrome
[152].
2.5. Metabolism of Ghrelin. The metabolic clearance rates of
acyl and desacyl-ghrelin injected by bolus in humans diﬀer
by several-fold [91]: Figure 4(a).A c t i v eg h r e l i n( 1μg/kg) is
removed more rapidly (half-life 21 minutes) than unmod-
iﬁed ghrelin peptide (36 minutes) and partitions into a
larger but ﬁnite distribution volume consistent with greater
lipophilicity. At a higher ghrelin dose (3μg/kg), half-lives
are 47 and 64 minutes for acylated and unacylated pep-
tide. This concentration-dependence suggests interconver-
sion of ghrelin isoforms and/or 2-compartment kinetics of6 International Journal of Peptides
acylated peptide [155]. Figure 4(b) illustrates that steady-
state bioactive-ghrelin concentrations are not saturable at
metabolic clearance rates of up to 60L/kg/day. Acylated
peptidebindstoplasmahigh-densitylipoproteinscontaining
paraoxonase (an esterase) [156], but the size and fate of
this reservoir are not known. An additional gastric ghrelin
deacylation enzyme has been identiﬁed, lysophospholipase
I[ 58]. The exact degree to which this enzyme regulates
ghrelin biosynthesis secretion is still unknown. Desacyl-
ghrelin appears to undergo signiﬁcant renal clearance [86],
whereas acylghrelin is extracted substantially by the liver
[142, 157].
3. Ghrelin(GHS)Receptor-1a
The ghrelin receptor exhibits high (about 50%) basal consti-
tutive activity [158, 159] and responds to inverse agonists,
partial agonists, and allosteric antagonists [160, 161]. In
particular, inverse agonists repress basal receptor activity,
as deﬁned by inositol-triphosphate, Ca2+, or diacylglycerol
signal generation [159, 162]. Since blood ghrelin levels rise
between meals and overnight, a ghrelin-receptor inverse
agonist might be used to minimize hunger at these times and
overnight [163]. In two families, short stature accompanied
GHS-R1a mutations that reduced constitutive GHS-R1a
activity [27], thereby implying biological relevance of basal
receptor activity.
M u l t i p l ee x p e r i m e n t a ls t r a t e g i e sh a v eb e e ne m p l o y e d
to test the biological impact of silencing ghrelin or GHS-
R1a activity: Table 2. Consistent outcomes in animal models
comprise loss of appetitive, locomotor, and somatotropic
regulation by exogenous ghrelin; modest reduction of body
weight, IGF-I concentrations, and GH pulses in the female
animal; increased fat oxidation; a rise in mean arterial blood
pressure; reduced obesity and improved glucose tolerance,
but with a potentially higher risk of hypoglycemia during
prolonged fasting; and decreased development of fatty diet-
induceddiabetesmellitus[164–168,174–185].Doubletrans-
genic knockout of ghrelin and cognate receptor is marked by
diminished adult body weight, greater energy expenditure,
and higher locomotor activity [169, 186]. Thus, GHS-R1a
is a physiological mediator of ghrelin’s stimulation of GH
secretion, repression of oxygen consumption and locomotor
activity, and enhancement of appetite. GHS receptor type 1b
arises from a nonspliced transcript, whose product does not
bind acylghrelin or confer known bioactivity [5, 187].
Unlike ghrelin, synthetic GHS’s acting via GHS-R1a
typically do not require acylation and are not known GOAT
substrates. Moreover, multiple biological eﬀects have been
reported for desacyl-ghrelin, which essentially does not bind
GHS-R1a. A partial registry of eﬀects comprises diﬀeren-
tiation of skeletal muscle; relaxation of vascular smooth
muscle; suppression of proinﬂammatory cytokines; inhibi-
tion of apoptosis of cardiomyocytes, pancreatic beta cells,
and endothelial cells; antagonism of ghrelin’s stimulation
of somatic growth, hepatic gluconeogenesis, and appetite;
hypotensive eﬀects; repression of fatty-acid oxidation; and
stimulation of adipogenesis [22, 75, 188–201]: Table 3.
Table 2: Experimental strategies for verifying ghrelin action.
Genetic
(1) transgenic silencing of ghrelin gene
(2) transgenic silencing of ghrelin receptor
(3) double knockout
(4) antisense transgene to neuronal ghrelin receptor
(5) overexpression of ghrelin
Immunologic
(1) immunoneutralization
(2) catalytic antibodies
Antagonists
(1) peptides
(2) nonpeptides
(3) RNA Spiegelmer
Infusion of ghrelin or desacyl-ghrelin
(1) agonism and antagonism
Anatomic deﬁnition of ghrelin-neural network
(1) transgenic green ﬂuorescent protein-linked ghrelin
Selected References: [11, 65, 164–173]
Although local acylation could explain certain actions of
unacylated ghrelin, other eﬀects that oppose or diﬀer from
those of acylated peptide raise the possibility of non-GHS-
R1a mediation. Synthetic analogs of ghrelin likewise may
exhibit partial agonism (e.g., stimulation of appetite but not
GHrelease,andviceversa),antagonism,andinverseagonism
despite similar GHS-R1a binding aﬃnities [160, 202–207].
To date, no desacyl-ghrelin and no other GHS receptors have
been cloned to explain such data [175].
Acylghrelin, unlike the naked peptide, is a consistently
eﬀective agonist of GH secretion in multiple species from
ﬁsh to mammals [34, 65, 215–221]. Nonacylated synthetic
GHS can stimulate GH secretion in occasional models [222–
224]. In ﬁsh, desacyl-ghrelin may function as an inhibitor
of ghrelin’s stimulation of appetite and locomotion [225]. In
mice, transgenic overexpression of desacyl-ghrelin decreases
food intake, gastric emptying, GH (female animal) and
IGF-I (both sexes) concentrations, body weight and length,
and GH release induced by exogenous ghrelin [75]. CNS
delivery of desacyl-ghrelin in the rat likewise impedes
food intake and gastric emptying [190, 196]. In humans,
exogenous desacyl-ghrelin does not restrict ghrelin-induced
GH secretion but disinhibits ghrelin’s repression of insulin
secretion [210, 221, 226]. Acylated ghrelin, unlike GHRH,
does not induce GH-gene transcription. Exceptions include
the pituitary glands of embryonic ﬁsh and prepubertal rats
in vivo and ovine somatotropes in vitro [227–229]. Both
GH and IGF-I can feed back to inhibit hypothalamopituitary
stimulation by ghrelin/GHS, but feedback inhibition is less
marked on GHS than GHRH stimulation [111]. Feedback
appearstoinvolveinductionofperiventricularhypothalamic
somatostatin outﬂow [230], which quenches both GHRH
and GH secretion [4].International Journal of Peptides 7
Table 3: Reported actions of desacyl-ghrelin.
Eﬀect of desacyl-ghrelin Compared with acylghrelin Reference
shared or opposite
Adipocytes
(1) ↓ fat oxidation
(2) ↑ glucose uptake
(3) ↑ diﬀerentiation shared [195, 199]
(4) ↑ hypertrophy
(5) ↓ lipolysis
anorexigenic opposite [190, 196]
Antiapoptotic
(1) islet beta cells shared [22, 194]
(2) cardiomyocytes
antiinﬂammatory shared and unshared [188, 200]
body weight opposite [75]
cardioprotection shared [194, 201]
gastric motility opposite [196, 208]
↓ hepatic gluconeogenesis opposite [198]
hypotension shared [197]
locomotion unknown [209]
↑ insulin sensitivity opposite [210]
neurogenesis shared [211–214]
skeletal-muscle diﬀerentiation shared [193]
↓ somatic growth opposite [75]
vascular smooth-muscle relaxation similar [197]
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Figure 4: Strong impact of bolus ghrelin dose and ghrelin isotype (acylated [bioactive] or total ghrelin) on the metabolic clearance rate
(MCR) of ghrelin in postmenopausal women. Means with diﬀerent superscripts diﬀer signiﬁcantly by post hoc analysis after ANOVA (P
=.003) (a). Linear relationship of steady-state MCR of acylated ghrelin to plasma acylghrelin concentration during constant ghrelin infusion
(b). Adapted from [91] with permission.8 International Journal of Peptides
4.GhrelinandGHRHSynergy
Active ghrelin acts as an ampliﬁer of GHRH, the
primary agonist of GH secretion [4]. Human and murine
hypothalami contain a wide network of ghrelin-expressing
neurons, which extends across the arcuate, ventromedial,
paraventricular and multiple other nuclei [8–11, 231–235].
Antisense RNA-mediated silencing of the murine GHS-1a
receptor localized to GHRH neurons resulted in reduced
adult weight, fat mass, pulsatile GH secretion, and IGF-I
production in the adult female only [165]. Arcuate-nucleus
GHRH-gene expression also declined in these animals
[236], indicating that GHS-R1a not only transduces GHRH
release but also maintains GHRH gene transcription
[237, 238]. Consistent with this inference, GHS’ stimulation
of maximal (5-35-fold) GH release requires an intact
hypothalamopituitary unit allowing GHRH outﬂow to
the pituitary [239–242]. Accordingly, GHRH (−/−)m i c e ,
GHRH-receptor (−/−) mice, and rare patients with
inactivating mutations of the GHRH receptor or congenital
aplasia of the pituitary stalk are hyposomatotropic, and
respond sparingly (<3-fold) to ghrelin/GHS [241, 243–246].
Immunoneutralization of GHRH and antagonists of GHRH
also restrict GHS’s eﬀects markedly, resulting in responses of
somatotrope cells to GHS similar in magnitude to those in
inferred directly in vitro [1, 247].
Ghrelin or synthetic GHS achieves synergy with GHRH
(supraadditive stimulation of GH secretion) when a near-
threshold dose of GHS is combined with a maximally
eﬀective dose of GHRH in the human, rat, pig, cow, and
dog in vivo [248–255]. Synergism is not observed after
combined stimulation with either maximal GHRH and
maximal GHS or submaximal GHRH and maximal GHS
stimulation [65, 254]. Synergistic stimulation of GH release
is absent in pituitary cells cultured in vitro and in patients
with destructive lesions that separate the hypothalamus
and pituitary gland [65, 216, 219, 242, 250, 256, 257],
thus deﬁning a critical role for joint hypothalamopituitary
eﬀects. Nonetheless, precise mechanisms subserving synergy
are not established. Proposed mechanisms include ghrelin-
mediated (a) opposition to hypothalamopituitary actions
of SS and/or (b) stimulation of an unknown (“U”) syn-
ergy factor [4, 29, 65, 151, 255, 258–260]. A substance like
galaninoranendogenous opiatergicpeptide might represent
such a factor, since both peptides release and synergize
with GHRH and their neurons innervate periventricular
SS neurons [261–267]. Reduced pituitary action of SS is
unlikely to be the sole potentiating mechanism subserving
GHS action, since GHS and GHRH synergize even after
immunoneutralization of SS [268]. Although GHRH can
induce the pituitary ghrelin and GHS-R1a genes [42], the
physiological impact of this potentially amplifying mecha-
nism is not known.
Since highly selective GHS-R1a antagonists are not avail-
able for clinical investigation, determining the exact extent
to which endogenous ghrelin participates in amplifying GH
secretioninhumanphysiology,includinginutero,ininfancy,
childhood, puberty, adulthood, and senescence remains
diﬃcult [4, 65, 250]. Nonetheless, mutational reduction of
constitutive ghrelin-receptor activity in humans is associ-
ated with short stature [27]. Conversely, overexpression of
neuronal GHS-R1a in female mice elevates GH and GHRH
gene expression [28]. In addition, prolonged administration
of ghrelin or synthetic GHS in humans augments GH, IGF-
I and IGFBP-3 concentrations and lean-body mass, and
diminishes total-body fat, while eliciting transient secre-
tion of adenocorticotropin hormone (ACTH), cortisol, and
prolactin [64, 269–273]. The last observation is signiﬁcant,
because higher doses of ghrelin/GHS evoke ACTH, cortisol,
and prolactin secretion acutely in humans and animals,
putativelybyinducinghypothalamicsecretionofoneorboth
primary ACTH-releasing peptides, corticotrophin-releasing
hormone (CRH), and arginine vasopressin (AVP) [272,
274–278]. How GHS induces prolactin release is not clear.
Doubling or tripling plasma ghrelin concentrations evokes
GHsecretioninhumanswithoutmeasurablyalteringACTH,
prolactin, insulin, or free fatty-acid concentrations [279].
The basis for the dose-response diﬀerence and tachyphylaxis
of the corticotropic, but not the GH-releasing, eﬀect of
G H Si sn o ty e te v i d e n t[ 280]. Likewise, why age and obesity
impair GHS-induced secretion of GH but not of ACTH and
prolactin is not known [113, 281].
Depending upon chemical structure and dose, synthetic
GHS can stimulate GH secretion after intranasal, oral, s.c.,
or i.v. administration [4, 65, 250, 272, 282, 283]. Entry of
acylghrelin (but not desacyl-ghrelin) into and exit of the
same from the brain is via structurally selective saturable
transport [284–286]. Since hypothalamic GHRH release is
prerequisite to maximal GH stimulation, GHSs have clinical
therapeutic potential in treating: (i) idiopathic short stature
in patients with preserved CNS outﬂow of GHRH [64, 287–
290]; (ii) hyposomatotropism in aging, wherein GHRH
release may be diminished but is not absent [271, 291, 292];
(iii) hyposomatotropism associated with visceral
adiposity, including the HIV lipodystrophy syndrome
[167, 179, 190, 293–295]; and (iv) conditions of partial GH
resistance accompanying anorexia, cachexia, or heightened
catabolism, such as metastatic cancer, hepatic or renal
failure, chronic obstructive pulmonary disease, systemic
inﬂammation, and advanced heart failure [133, 250, 296–
298]. Preclinical data in these areas and clinical data
in healthy subjects suggest the merit and feasibility of
more comprehensive investigations [270, 271, 299–301],
since prospective, double-blind, placebo-controlled trials
are lacking. Critical issues to be resolved include long-
term safety, duration, eﬃcacy, and indications for GHS
administration in selected GH-deﬁcient states.
5.MultifacetedActions
Short-term ghrelin/GHS administration stimulates GH
secretion, locomotor activity, and appetite, increases plasma
free fatty acids, imposes mild peripheral (muscle) insulin
resistance, suppresses insulin secretion, inhibits fat oxida-
tion, and promotes adipocyte glucose metabolism [4, 65,
170, 209, 210, 302–307]. Moreover, GHS is both antiprolifer-
ative and proliferative depending upon cell type [308–310].International Journal of Peptides 9
These and other multifaceted actions of ghrelin are discussed
next.
5.1. Appetitive Eﬀects of Ghrelin. Ghrelin consistently
enhances appetite by 25%–30% in fasting humans and
animals with the possible exception of chicken, quail, and
sheep [37, 39, 295, 311–315]. Endogenous ghrelin may
enhance anticipatory motor activity, before scheduled meals
[316]. Active ghrelin stimulates and suppresses glucose-
sensitive neurons in the lateral and ventromedial hypothala-
mus, respectively, stimulating hunger and inhibiting satiety
[317]. The orexigenic eﬀect arises by combined activa-
tion of neuropeptide Y/agouti-related peptide (NPY/AGRP)
and orexin A neurons [314, 318–322]. Concomitantly,
acylghrelin antagonizes satiety-promoting and anorexigenic
signals, such as leptin [38, 323], corticotropin-releasing
hormone (CRH), cocaine and amphetamine-regulated tran-
script (CART), proopiomelanocortin (POMC), and alpha-
melanocyte-stimulating hormone (alpha-MSH) [324–326]:
Figure 5. Obestatin is not pictured because of its contro-
versial role in appetite. AGRP is an endogenous inhibitor
of alpha-MSH, thereby promoting positive energy balance.
Ghrelin may act in part by inducing the intracellular
signal mammalian target of rapamycin in AGRP neurons,
a messenger which promotes protein synthesis and limits
apoptosis [327]. Both NPY and AGRP participate in the
orexigenic action of ghrelin, since transgenic disruption
of both mediators is needed to quench appetite [303,
321]. The potent orexigen, orexin (hypocretin), which is
a key peptide in maintaining wakefulness [328], is also
involved in the appetitive action of ghrelin, in that orexin-
A immunoneutralization or receptor silencing attenuates
ghrelin’sorexigenicaction[329].Akeyneuronalbiochemical
mediator of energy-depletion mediated appetitive drive may
be the low-ATP sensing protein kinase, AMP kinase, which
is stimulated by ghrelin and cannabinoids [330]. Desacyl-
ghrelinexertsoppositeeﬀects,namely.decreasesfoodintake,
fat mass, and gastric emptying [190, 293]. Ghrelin also
suppresses pancreatic beta-cell insulin secretion, which may
contribute to orexigenesis, given that insulin can function as
a CNS satiety signal [331].
T h ep e r i p h e r a lv a g u sn e r v ea n di t sd o r s a lm o t o rn u c l e u s
in the brainstem and ventral tegmental neurons medi-
a t es o m eo fs y s t e m i cg h r e l i n ’ sa p p e t i t i v ee ﬀects [332–
336]. Hunger-suppressing vagal aﬀerent impulses from the
stomach are subdued by ghrelin and by other orexigenic
hormones, acting via the GHS-R1a, cannabinoid-1 (CB-
1), and melanin-concentrating hormone-1 (MCH-1) and
activated by anorexigenic receptors, like cholecystokinin-A
(CCK-A), peptide YY (3–36), and glucagon-like peptide-1
[334,337]:Figure 6.Infact,aCB-1antagonistimpedesghre-
l i n ’ sa p p e t i t i v ee ﬀect, illustrating key facilitative interactions
[338]. In addition, a CCK antagonist abolishes the capability
of intraduodenal fat to suppress gastric ghrelin secretion
[339], consistent with gastroduodenal feedback [340]. The
dorsal motornucleus of thevagusexpresses GHS-R1a,which
modulates limbic-system dopamine- and brainstem gaba,
glutamine, and noradrenergic transmission to hypothalamic
appetitive and satiety centers [335, 341–343]. Dorsal vagal
neuronal GHS-R1a levels may decline with aging in the rat
[344]. Ghrelin crosses the blood-brain barrier and directly
inhibits leptin neurons and stimulates NPY/AGRP and
orexin neurons [333], which are located, respectively, in
the arcuate nucleu and lateral hypothalamus. MCH inhibits
lateral hypothalamic neurons, providing additional feedback
control [345]. Inhibition of brain (rather than exclusively
peripheralvagal)GHS-R1aseemstoexplaintheanorexigenic
properties of ghrelin antagonists [346, 347].
Although genetic disruption of GHS-R1a abrogates
orexigenic stimulation by ghrelin, cachexia does not develop
in the transgenic animals, including those with combined
ghrelin and GHS-R1a knockout, putatively reﬂecting signal
redundancy within nutritional networks [167, 353–355]. In
particular, pathways mediating orexigenesis and satiety are
convergent, oppositional, adaptive, and complex [186, 295,
319, 356–358], involving hormones from endocrine glands
as well as gut mucosa and vagal aﬀerent signals [35, 38,
359–362]. For example, intestinal mucosal L-cell-derived
oxyntomodulin, a satiety signal, acts via the hypothalamus
to inhibit vagally driven gastric secretion of acylghrelin,
thus quelling hunger [363]. Plasma leptin and ghrelin
concentrations tend to vary inversely in various clinical
settings [364], and CNS leptin is a strong ghrelin antagonist
[35], possibly by modulating NPY-Y1 or Y5 signaling [8,
38]. GHS-R1a is subject to systemic modulation, including
upregulation by thyroxine and E2 and downregulation by
glucocorticoids and GH [122]. In addition, E2 inhibits the
acute orexigenic eﬀect of exogenous ghrelin in the male
and female rat [123]. Accordingly, the ghrelin system is a
pivotal but nonexclusive member of a robust nutritional
network in mammals [10, 294, 314, 319, 365–368]. However,
ghrelin reduces food intake in neonatal chickens, possibly by
elevating brain fatty-acid synthesis [369].
GHS receptors are located in the stomach, gastroin-
testinal myenteric plexus, vagal nodose ganglion, dorsal
motor nucleus of the vagus, arcuate-nucleus orexigenic
neurons, such as NPY/AGRP and orexin A-expressing cells,
anorexigenic neurons that are either leptin-sensing or leptin-
producing, and multiple other unidentiﬁed neurons [314,
370, 371]. Silencing any one of NPY, AGRP or orexin-A-
receptorgeneslimitsbutdoesnotabolishghrelin’sorexigenic
eﬀect [329, 372–374]. Triple negation of NPY, AGRP, and
orexin is necessary to eliminate ghrelin’s appetitive eﬀect
[375]. Small interfering DNA-mediated neutralization of
paraventricular neuronal GHS-R1a in rats imposes weight
loss and reduces serum ghrelin without altering food intake,
suggesting eﬀects on energy expenditure as well [376].
Network robustness is conferred by the facts that ghrelin
activates whereas leptin represses both NPY/AGRP, and
orexin neurons; orexin A potentiates (feeds forward onto)
NPY release via the orexin-1 receptor; NPY represses orexin
release via NPY-Y1 receptors; neuropeptide W and galanin-
likepeptidefurthermodulateorexinneurons[377,378]NPY
and orexin, respectively, suppress (feed back) and induce
(feed forward onto) the potent anorexigens, leptin, and
proopiomelanocortin, which in turn feed back on ghrelin-
ergic cells [186, 235, 379–387]. Moreover, NPY and ghrelin10 International Journal of Peptides
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Figure 5: Basic ghrelin network inﬂuencing locomotion (left upper quadrant), gastrointestinal signals to appetitive and anorexigenic centers
(middle section), gastric motility (right upper quadrant) or peripheral target tissues (right lower segment). Unpublished schema.
neurons synapse on themselves, suggesting autofeedback-
dependentregulation[235].Collectivefeedforward/feedback
circuits presumably subserve enhancement and suppression
of food intake in a manner deﬁned by sex, species, age, phys-
ical activity, ultradian rhythmicity, and sleep-wake cycles
[35, 231, 295, 328, 388]. For example, sleep curtailment may
augment appetite by simultaneously lowering circulating
leptin and elevating ghrelin levels. The latter correlates with
meal initiation [389]. These and other experiments illustrate
the complex adaptability of nutritionally regulated neural
networks [234, 278, 353, 362, 390].
A 23-amino-acid C-peptidyl fragment of preproghrelin,
named obestatin, has not fulﬁlled its original nomencla-
ture as an antagonist of ghrelin’s orexigenic eﬀects [394–
399]: Figure 7. In addition, transgenic knockout of the
proposed obestatin receptor, GPR39, does not aﬀect food
intake [394, 396, 400, 401]. Whereas obestatin (probably
better termed, ghrelin-associated peptide) does not alter
pituitaryhormonesecretion[402],thispeptidemaysuppress
thirst, promote beta-cell survival and regeneration, activate
urocortin-2 pathways and thereby inhibit gastroduodenal
peristalsis,andinduceearly-responsegenesingastricmucosa
and preadipocytes [403–410]. A physiological distinction
pertinent to CNS actions of ghrelin, but not obestatin, is
that only ghrelin exhibits speciﬁc saturable binding to and
endocytosis by cerebral microvessel endothelial cells, thereby
allowing measurable permeation of the blood-brain barrier
[284, 286]. However, obestatin attenuates the hypothermic
eﬀect of preproghrelin gene deletion [411].
Transgenic overexpression of CNS and gastric ghre-
lin causes hyperphagia, increases energy expenditure, and
decreases sensitivity to insulin and leptin in mice [170].
The orexigenic action of ghrelin does not seem to wane
in this model, since adult transgenic animals continue to
eat excessively after fat depots reach a maximum [412]. In
a second model, 8 weeks of GHS treatment maintained
orexigenesisintherat[413].Inathirdmodel,overexpression
of GHS-R1a in GHRH neurons increased organ and muscle
weight, while decreasing body fat in female animals [28].
Conversely, in a fourth model, transgenic reduction of
GHS-R1a expression on GHRH neurons suppressed both
GHRH and NPY gene expression, thereby diminishing GH
and fat mass in the female [236]. In patients with renal
or cardiac failure or chronic lung disease and cachexia,
short-term (up to 3 weeks) administration of ghrelin once
or twice daily may stimulate appetite and weight gain
as assessed in uncontrolled studies [298–300, 414, 415].
However, in the perioperative orthopedic setting, ghrelin
infusions for 3 weeks did not improve overall functional
physical performance [416]. Nonetheless, the precise extent
to which GHS agonists and antagonists will alter hunger
or satiety over the longterm remains diﬃcult to forecast
[74, 232]. This issue is important since studies with leptin,
an anorexigenic adipokine that antagonizes ghrelin, revealed
tachyphylaxis to satiety-promoting eﬀects [186, 417].
Ghrelin itself undergoes tissue-speciﬁc regulation by
short-term fasting, hypoglycemia, and nutrient depriva-
tion. These factors depress brain ghrelin expression, while
promoting gastric ghrelin secretion and amplifying CNS
responses to ghrelin [9, 418, 419]. In species in which
desacyl-ghrelin can antagonize the orexigenic eﬀects of
acylghrelin [293], regulation of GOAT activity in bothInternational Journal of Peptides 11
Table 4: Cardiovascular actions of GHS.
↓ mean arterial pressure
↑ inotropy (myocardial tension generation)
↓ lusitrophy (tension relaxation)
↓ ventricular end-systolic pressure
↓ cardiomyocyte apoptosis
↓ endothelial apoptosis
↓ pulmonary hypertension
↑ renal perfusion
↑ coronary perfusion pressure
↑ left-ventricular ejection fraction
↓ oxygen consumption
↓ cardiac sympathetic drive
Selected References: [15, 22, 194, 197, 201].
the stomach and brain may be important to appetitive
homeostasis [191, 196]. GHS analogs that do not require
acylation have the merit of bypassing GOAT [420].
Gastric-bypass procedures, especially when combined
with truncal vagotomy, often reduce serum total ghrelin
concentrations initially [426, 427]. In principle, reduced
ghrelin availability would further attenuate adipogenesis
[191, 195, 199]. However, in some studies prolonged weight
loss after gastric bypass had no eﬀect on fasting ghrelin
levels [250, 428, 429] or reduced only acylated ghrelin [430].
In rodents, vagotomy impedes both appetitive and GH-
stimulatingeﬀectsofghrelin[334,336,431,432].Inhumans,
pharmacologic or surgical interruption of vagal cholinergic
traﬃc lowers ghrelin concentrations and blunts appetitive
stimulation but does not block GHS-induced GH release
[336, 431, 433].
5.2. Insulinostasis. Ghrelin inhibits insulin (beta cells) and
somatostatin (delta cells) but stimulates glucagon (alpha
cells), secretion in vivo and in isolated pancreatic islets
in vitro [304, 434–439]. Some early studies reported that
GHS induces insulin secretion [440]. Inconsistencies may
reﬂect the capabilities of desacyl-ghrelin to suppress hepatic
glucose production and/or block acylghrelin’s inhibition of
insulin secretion [198, 221, 434, 441]. Other studies did not
control for the fact that acutely elevated GH and glucose
concentrations (induced by GHS) stimulate insulin secretion
acutely. GHS receptors are expressed by both beta and alpha
cells [442]. Ghrelin’s inhibition requires Gi, which activates
outward K+ currents and disables inward Ca2+ ﬂux [443,
444]. These eﬀects particularly impede rapid ﬁrst-phase
insulin release [444]. Moreover, acylghrelin antagonizes
peripheral insulin action (muscle > liver), which eﬀect is
reversed by desacyl-ghrelin in GH-deﬁcient adults [210].
However, desacyl-ghrelin has little if any eﬀect on glucose,
insulin, free fatty acid, or GH releases in (obese) humans
[445].
From a reciprocal perspective, insulin and somatostatin
repress, whereas glucagon induces the gastric ghrelin gene
in the rat [88, 124, 130]. In humans, glucagon injection
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Figure 6: Complementarity of ghrelin’s vagal-nerve signaling via
GHS-R1a with that of other orexigenic (left) or anorexigenic (right)
peptides. PYY: polypeptide YY; GLP-1: glucagon-like peptide.
Unpublished sketch.
inhibits ghrelin secretion [121], but via uncertain pathways.
In rodents, insulin represses not only gastric but also
CNS preproghrelin expression [446]. In accordance with
insulin’s negative eﬀects, hyperinsulinemia associated with
hepatic or skeletal-muscle insulin resistance and/or obesity
correlates inversely with fasting ghrelin concentrations [71,
447, 448]. An exception is the genetic Prader-Willi syndrome
marked by obesity, mild insulin resistance, and unexplained
hyperghrelinemia with increased numbers of gastric ghrelin-
expressing cells [449–451].
Adult pancreatic islets express relatively little ghrelin
protein and few GHS receptors, but fetal and neonatal
islets exhibit abundant ghrelin gene transcripts and pep-
tide in epsilon cells [452–454]. Although both acyl and
desacyl-ghrelin promote beta-cell regeneration [408, 455],
endogenous pancreatic ghrelin inhibits beta-cell function,
since perfusion of the pancreas with ghrelin antiserum
augments insulin secretion [408, 438, 444, 456]. In addition,
genetic knockout of ghrelin and administration of GHS-
receptor antagonists diminish fasting hyperinsulinemia and
enhance glucose tolerance in rodent models [205, 439, 443,
444]. Thus, in knockout ghrelin mice, increased constitutive
ghrelin-receptor activity may result in increased insulin
secretion, which would be susceptible to inhibition by a GHS
receptor antagonist with inverse agonist activity. Further
investigations are required to appraise the inﬂuence of diet,
age, gender, species, and obesity on pancreatic actions of
ghrelin, given the high importance of drug development in
this area. A desirable ghrelin antagonist would limit appetite,
disinhibit insulin secretion, and minimize adiposity (by
favoring fat oxidation) in patients at risk for the metabolic
s y n d r o m eo rt y p eI Id i a b e t e sm e l l i t u s[ 84, 205, 223, 457,
458]. Table 4 highlights some of these issues and identiﬁes
potential adverse consequences of prolonged GHS-receptor
blockade.12 International Journal of Peptides
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5.3.CardiovascularEﬀects. AtdosesthatinducemaximalGH
secretion, ghrelin and GHS can exert direct vasodilatory,
cardiotropic, and brainstem-mediated hypotensive eﬀects,
typiﬁed by a 10%–20% decrease in mean arterial blood
pressure and an increase in left-ventricular ejection fraction
[14, 183, 201, 459–464]. Desacyl-ghrelin also causes vasodi-
lation and opposes cardiomyocyte and endothelial apoptosis
[194, 465]. Conversely, a ghrelin antagonist elevates heart
rate and arterial pressure in the conscious rat [183]. The
mechanismsofghrelin’seﬀectsincludecentralsuppressionof
sympatheticcardiacdrive,systemicvasodilation,antagonism
of angiotensin II and endothelin-induced vasoconstriction
including of the pulmonary arteries, and potentiation of
nitric oxide-mediated relaxation of vascular smooth muscle
[14, 20, 197, 465–471]: Table 4. GHS receptors exist on
endothelium, vascular smooth-muscle cells, and cardiomy-
ocytes [13, 201, 472, 473]. Furthermore, ghrelin transcripts
and protein are expressed in endothelial cells and cardiac
muscle [466, 472]. Both ghrelin and desacyl-ghrelin reduce
the rate of myocardial tension generation (negative inotropic
eﬀect) and the rate of tension relaxation (negative lusitropic
eﬀect), possibly in part independently of the GHS-1a
receptor [13, 201, 330, 474]. Obestatin does not initiate these
responses [475]. The membrane glycoprotein, CD36 initially
recognized as a macrophage type B LDL-scavenger receptor
and recently as a fatty-acid binding protein, may transduce
or modulate certain cardiovascular and anti-inﬂammatory
eﬀects of ghrelin [188, 207, 474].
The capability of ghrelin to limit apoptosis of endothelial
cellsandcardiomyocytesinvitrointroducesthepossibilityof
reducing endothelial dysfunction associated with atheroscle-
rotic risk [476–478] and salvaging myocardium in zones
of marginal chemotoxicity [479] or ischemia [22, 194, 461,
480]. Desacyl-ghrelin shares cardioprotective eﬀects, but the
mechanism is not known [194]. Increased coronary-artery
perfusion pressure, reduced cardiac sympathetic activity,
antagonism of L-type Ca2+ channel-mediated contractility,
and activation of low-energy AMP-kinase may contribute to
cardiotropism [461, 481, 482]. Resultant eﬀects are reduced
Table 5: Reported modulatory messengers of ghrelin.
Messenger/mediator Site/mechanism
(1) phospholipase C GHS receptor-transfected cells
(2) protein kinase C neurons
(3) cAMP potentiation pituitary
(4) nitric oxide vasculature
(5) urocortin-2 receptor pancreas, stomach
(6) mitogen-activated protein
kinase cardiomyocytes
(7) extracellular-regulated
kinase cardiomyocytes
(8) potassium and calcium
channels islets, somatotropes
(9) AMP kinase neurons, gastric mucosa
Selected References: [21, 22, 208, 238, 294, 348–352].
left-ventricular endsystolic volume and increased cardiac
output[414,460]:Table 5.Howmuchofthisbeneﬁtisdueto
stimulatedsecretionofGH,whichexertscardiotropiceﬀects,
is not known [483].
Elevated ghrelin concentrations in patients with chronic
heart failure may indicate a compensatory mechanism in
particular [484] or reﬂect partial tissue resistance to ghrelin
in cachetic states more generally [83, 485]. Three- and
four-week pilot studies of exogenous ghrelin’s anabolic
and anticatabolic eﬀects in chronic cardiac cachexia in
the rat and human seem favorable [194, 301, 461, 486],
although parallel-cohort prospectively randomized double-
blind controlled clinical studies are not available [414].
Collective data invite more rigorous interventional studies in
experimental models of both early and advanced myocardial
injury and failure. In addition, further investigations are
necessary to assess how GHS aﬀects perfusion of the brain,
skeletal muscle, kidney, liver, and intestine [296, 487].
5.4. Gastric Motility. Ghrelin is expressed in granules in
gastric X/A-like oxyntic cells [489, 490] .T h es a m eg r a n u l e s
contain immunoreactive motilin, a comparably strong but
distinct prokinetic peptide [491, 492]. Obestatin is addition-
ally present in many of the same cells, but its gastrointestinal
function is not known [189, 404]. In one report, obestatin
was able to elicit pancreatic zymogen secretion [493]. In
other contexts, desacyl-ghrelin and obestatin, unlike ghre-
lin, inhibit gastric antral contractions [189]. Ingestion of
medium-chain triglycerides in the infant or adult enhances
gastric acylghrelin concentrations [494, 495]. Inactivation of
prohormone convertase 1/3 (apreproghrelin endopeptidase)
also increases ghrelin gene transcripts, suggesting negative
f e e d b a c kb yg h r e l i no ni t so w nt r a n s c r i p t i o n[ 496]. Fasting
induces the preproghrelin gene in ﬁsh and mammals via
eﬀerent vagal cholinergic signals [497–499]. The cephalic
(meal-visualization) phase of digestion in humans clearly
depends on vagal eﬀerents, which transduce prandial inhibi-
tionofghrelinsecretion[500].Insheep,cholinergicblockade
stimulates stomach ghrelin output [311], suggesting baseline
cephalic phase-like inhibition in this species.International Journal of Peptides 13
Motilin and ghrelin receptors are 36% homologous in
peptide sequences; yet each is activated principally by the
homologous agonist at physiological concentrations [492,
501, 502]. Further unlike GHS-R1a, the motilin receptor
exhibits little constitutive activity. The GHS-R1a gene is
conserved with 58% nucleotide homology in puﬀer ﬁsh and
humans [63]. The receptor is present in the myenteric (neu-
ronal) plexus, gastroduodenal mucosa, smooth muscle, and
vagal nodose ganglia [503, 504]. Ghrelin stimulates smooth-
muscle contractions and type III primary migrating-motor
complexes in the stomach and proximal duodenum of the
eel, rat, rabbit, mouse, guinea pig, and human; inhibits
postprandial contractions (dog) and gastric accommoda-
tion (decreases residual stomach volume); and promotes
gastric-acid secretion, which facilitates protein hydrolysis
and Ca2+ absorption [505–511]. Current promotility drugs
for the treatment of idiopathic, postvagotomy and diabetic
gastric atony, and morphine-induced postoperative ileus
include serotoninergic-3 agonists, dopamine antagonists,
and motilin-receptor agonists, like erythromycin [492, 512–
514]. Whereas desacyl-ghrelin may block certain promotility
eﬀects of ghrelin [208], ghrelin is unique in acting on
all four of gastroduodenal myenteric neurons, smooth-
muscle cells, the vagus nerve, and brain GHS-1a receptors
to augment gastric emptying and lower pH [333, 512].
An additional eﬀect is gastroprotection against alcohol and
ischemic mucosal stress [515]. Histamine-2 agonists and
gastrin synergize in promoting preprandial acid secretion
[516, 517], thus illustrating intragastric interactions with
ghrelin.
Preclinical and clinical data indicate that GHS-receptor
agonists can accelerate gastric emptying even in the pres-
ence of autonomic denervation, and reduce postoperative
gastrointestinal ileus [492, 506, 509, 511, 512, 518–522].
Patients with diabetic gastroparesis may have low plasma
total ghrelin levels, possibly due to vagal denervation and/or
chronic glucagon excess [121, 523, 524]. What is unclear is
the risk/beneﬁt ratio of systemic GHS treatment in patients
with GI bleeding, autonomic neuropathy, and/or concurrent
postoperativeneedsfornarcotics,anticholinergics,andother
drugs. Concerns would include possible hypotension due
to GHS-mediated relaxation of vascular smooth muscle
and negative cardiac inotropy and possible deterioration of
glucose tolerance due to suppression of insulin secretion and
augmentation of hepatic glucose output [198]. Thus, high
agonist selectivity will be necessary to ensure clinical safety.
5.5. Sleep-Wake Regulation. Ghrelin concentrations rise dur-
ing the ﬁrst four hours of normal sleep in humans [525]. The
mechanism is not known. Viewed conversely, ghrelin admin-
istration enhances slow-wave (non-REM) sleep including in
young and older men but not women [526–530]. In one
clinicalstudy,theGHSpeptide,hexarelin,reducednon-REM
sleep whereas GHRP-6 increased the same, suggesting GHS-
receptor pleiotropy or multiplicity [531]. How ghrelin can
enhance deep sleep and yet activate orexin-A neurons [328],
which are coupled to arousal-wakefulness and appetite,
is not yet clear [328, 532]. In addition, why patients
with obstructive sleep apnea, albeit obese, have elevated
acylghrelin concentrations has not been elucidated [533].
However, reduction of hypoxic episodes decreased ghrelin,
suggesting that ghrelin is a stress-responsive hormone.
5.6. Cell Survival and Cachexia. Ghrelin and GHS analogs
exert diﬀe r e n t i a t i v ea sw e l la sp r o l i f e r a t i v ea n da n t i p r o l i f -
erative eﬀects in vitro and in vivo [193, 211, 455, 534].
Examples include mitogenic and antiapoptic actions on pan-
creatic islets, spinal-cord, cortical and brainstem neurons,
osteoblasts, fetal lung branches, endothelium, cardiomy-
ocytes, and adipocytes on the one hand, and apoptotic
eﬀects in certain adrenal, lung, and prostate cancer cell
lines on the other hand [15, 21, 22, 192, 211–213, 309,
391, 480, 535–541]. Several cell-cycle eﬀects can be induced
by incubation with either acyl- or desacyl-ghrelin, raising
the possibility of involvement of both GHS-R1a and non-
GHS-R1a receptor pathways [58, 537]. This reﬂects the
fact that GHS-1a is essentially unresponsive to desacyl-
ghrelin [22, 177]. Short-term ghrelin/GHS administration
to enhance neuronal regeneration after ischemic or toxic
insults thus represents another major point of potential
therapeutic focus [214, 542, 543]. Because ghrelin can also
stimulate proliferation of certain carcinoma cell lines in vitro
[308,309,544],studiestoexcludelongtermoncogeniceﬀects
are needed.
Inasmuch as appetite wanes in the cachectic stage of
carcinomatosis, ghrelin is being evaluated as an anticachectic
agent. Studies in the rat, mouse, and human indicate that
ghrelin/GHS administration can dose-dependently enhance
appetite, body weight, and fat mass in several short-term
models of disseminated neoplasia [545–549]. Caveats are
that rigorous controls and blinding are often lacking, and
evaluations are necessarily of short duration initially. In
addition, some studies do not show orexigenic beneﬁts
[550, 551]. A preliminary study in 12 cachectic patients
with dialysis-dependent kidney failure showed appetitive
enhancementbyghrelincomparedwithrandomizeddouble-
blind placebo injection over a 1-week interval [415].
5.7. Adipogenesis. Prominent eﬀects of ghrelin/GHS
include direct promotion of preadipocyte proliferation
and adipocytic diﬀerentiation and hypertrophy [76, 552]:
Table 6. GH-independent CNS actions may participate in
lipogenesis [553]. Desacyl-ghrelin shares several of these
actions [191, 199]. Relevant mechanisms embrace repression
of insulin-sensitizing genes, such as adiponectin, and
induction of adipocyte leptin and peroxisome-proliferating
activator receptor- (PPAR-) gamma genes; stimulation of
endothelial lipoprotein lipase, adipocyte fatty acid synthase,
acetyl CoA carboxylase, and fat-cell glucose uptake; and
inhibition of fat oxidation via rate-limiting carnitine-
palmitoyl transferase [167, 171, 172, 191, 554, 555]. As
a more general metabolic mechanism, ghrelin mediates
inhibition of sympathetic outﬂow to thermogenic fat depots,
reduction of uncoupling protein-1 expression, and thereby
decreased resting energy expenditure [556, 557]. Species
appears to inﬂuence some mechanisms. For example, in14 International Journal of Peptides
Table 6: Adipogenic eﬀects of ghrelin.
(1) decrease fat-cell lipid export
(2) enhance lipoprotein lipase
(3) reduce insulin sensitivity
(4) stimulate preadipocyte proliferation
(5) promote adipocyte diﬀerentiation
(6) inhibit 5 -adenosine monophosphate protein kinase (AMP-kinase)
(7) augment hepatic glucose output and triacylglyceride content
(8) activate acetyl CoA carboxylase
(9) inhibit fatty acid oxidation
(10) induce leptin, sterol-response element binding protein-1c and
(11) PPAR-gamma
(12) suppress adiponectin
(13) increase appetite
Selected References: [44, 195, 198, 199, 210, 276, 293, 391–393].
sheep, ghrelin potentiates glucose-induced insulin secretion,
which is antilipoytic [558]. In rodents, unacylated ghrelin
can elevate insulin concentrations, which is adipogenic
[441]. Neither is the case in humans [210].
CNS pathways may participate in stimulating adipocyte
hypertrophy [171] and increasing the respiratory coeﬃcient
(increased ratio of glucose/fatty-acid oxidation) [234, 392,
555]. In particular, ghrelin acts in part by repressing leptin,
CRH, and histamine (anorexigenic) and activating orexin
and NPY (appetitive) signaling [184, 559–561]. Orexin A
in turn inhibits GHRH gene expression, thus limiting GH-
dependent lipolysis [562]. Thus, orexin contributes to fat
accumulation by augmenting appetite, attenuating satiation,
and restricting GH secretion [38, 171, 443].
Despite ghrelin’s strong adipogenic eﬀects, subcuta-
neous, visceral, and total adiposity correlate negatively
with blood ghrelin concentrations [116, 563]. This may
be because a signiﬁcant longterm eﬀect of ghrelin is to
drive pulsatile GH secretion, which is strongly lipolytic
[4]. Animal models indicate that ghrelin antagonists are
able to reduce hyperglycemia and adipogenesis, enhance
energy expenditure and fat oxidation, stimulate insulin
secretion and action, and heighten resistance to diet-induced
obesity [167, 168, 179, 182, 184, 205, 564]. A potential
risk of prolonged antagonist administration in the fasting
state could be endogenous insulin-induced hypoglycemia
[166], although this adverse event has not been observed in
humans.
5.8. Bone Formation. GHS-R1a and ghrelin peptide are syn-
thesized in bone cells, such as chondrocytes and osteoblasts
[12, 565]. Albeit moderately well understood in other
tissues, mechanisms mediating regulation of GHS-R1a in
bone remain unclear: Table 7.A c y l a t e da n du n a c y l a t e d
ghrelin stimulate osteoblast proliferation and diﬀerentiation,
increase osteoblastic markers like osteocalcin and bone alka-
line phosphatase, and repress osteoblast apoptosis putatively
via phosphatidylinositol 3-kinase and mitogen-activated
protein kinase signaling [566]. Moreover, in GH-deﬁcient
rodents, ghrelin administration augments Ca2+ retention in
Table 7: Key regulators of GHS-1a receptor.
Downregulation Stimulation
glucocorticoids (rodent) estrogen (VMN, stomach)
ghrelin (ﬁsh) thyroxine (rat)
certain promoter hyplotypes lactation (rat
hypothalamus/pituitary)
age (human brain) puberty (rat, pituitary)
GH (arcuate nucleus) GHRH (pituitary)
atherosclerosis (human)
ghrelin-responsive
corticotropinoma (human)
Selected References: [122, 187, 393, 421–425].
the skeleton, thereby elevating bone-mineral density [565].
The clinical impact of these eﬀects is not yet established.
5.9. Stress Adaptations. Recent studies point to a role for
ghrelin in modifying pathophysiological adaptations to
stress [275, 567, 568]. For example, ghrelin concentrations
rise acutely after major surgery along with inﬂammatory
cytokines like tumor-necrosis factor-alpha and interleukin
(IL)-6 [569]. In mice, transgenic knockdown of the ghrelin
receptor accentuates adverse eﬀects of chronic social-defeat
stress [570]. Analogously, ghrelin may permit adaptation to
pain, since it blocks spinal-cord nociceptive signals [571].
Lipopolysaccharide endotoxin stress lowers blood ghrelin
levels, causing an associated reduction in gastric emptying
[572]. The latter is substantially relieved by ghrelin infusion.
Under some conditions, desacyl-ghrelin inhibits gastric
contractions by activating stress-adaptive CRH receptor-2,
for which urocortin is the natural ligand [208, 348]. Ghrelin
also induces the anorexigenic hypothalamic CRH gene
[567], which normally stimulates ACTH release. Whether
CNS-mediated inhibition of food intake by desacyl-ghrelin
proceeds by activating the CRH pathway is not known [196].
Acute vascular-endothelial biochemical stress responses
are modiﬁed by ghrelin. This peptide induces nitric
oxide synthase (NOS) and represses the generation of
reactive oxygen species, thereby attenuating endothelial
injury [20, 573] .T h ep r o t e c t i v ee ﬀects require GHS-R1a,
phosphotidylinositol-3 kinase, and Akt/protein kinase B
[20].Along-termactionofghrelinmaybetoretardendothe-
lial apoptosis [574]. Ghrelin can also directly stimulate
humanvascularendothelial-cellmigration,buttheimpactof
this eﬀect is not so clear [575]. Substantial additional work is
needed to extend understanding of these aspects of ghrelin
pathophysiology.
5.10. Immune Modulation. Ghrelin, GHS receptors, GH,
and GH receptors are expressed in human monocytes and
Ba n dTl y m p h o c y t e s[ 576]. In general, ghrelin’s eﬀects
are antiinﬂammatory and immune-enhancing, for exam-
ple, diminution of monocytic, bacterial and endothelial
inﬂammatory factors driven by endotoxin exposure, sep-
sis, arthritis, interleukin 1 and 6, tumor necrosis factor-
alpha, and nuclear-factor kappa B [200, 577–579], andInternational Journal of Peptides 15
stimulation of proliferation of thymic epithelial cells and T
lymphocytes [580, 581]. Ghrelin also suppresses neutrophil
and macrophage migration, caspase activation, reactive
oxygen-species generation, and endoplasmic-reticular stress
activation [582–584]. The combined impact may be to
restrict lethal hepatic and pulmonary microvascular injury
in sepsis [515, 585–587]. Ghrelin concurrently induces
antiinﬂammatory cytokines, like interleukin-10 [578], and
augments organ perfusion pressure in sepsis [515, 588].
Sepsis-associated gastric mucosal injury, an additional cause
of mortality due to hemorrhage, is prevented in some
models [589]. Certain of these eﬀects may require the vagus
nerve [590]. In acute renal failure, ghrelin treatment can
repress inﬂammatory cytokines in the blood and brain,
limit protein catabolism, enhance food intake, and attenuate
renal injury due to endotoxemia and ischemia [415, 591–
594]. Total but not acylghrelin concentrations are elevated in
endstage renal failure [595] and normalize following kidney
transplantation.
Long-term surveillance of ghrelin and GHS receptor-
deﬁcient and ghrelin-overexpressing transgenic animals will
be needed to assess whether prolonged changes in ghrelin
availability inﬂuence immune function or inﬂammatory
disease.
5.11. GHS Administration in Protracted Critical Illness.
Although acute stress elevates GH secretion [596], extended
critical illness suppresses all three of GH, IGF-I, and IGFBP-
3 concentrations and inhibits tissue actions of GH. In
unfed patients with multiorgan failure, total ghrelin levels
rise [86, 131]. Infusions of GHS alone or combined with
GHRH substantially reverse biochemical markers of hypo-
somatotropism in this setting [597, 598]. However, recovery
from multiorgan failure and inﬂammation is necessary to
alleviate tissue resistance to GH [4]. In animal models,
ghrelin administration reduces sympathetic outﬂow, acute
renal failure, inﬂammation in the lung, stomach and liver,
and lethality of sepsis [200, 344, 515, 586–590, 599–601].
Contrastingly, glucocorticoid deﬁciency, and glucocorticoid
excess alter the GHS axis by, respectively, diminishing blood
ghrelin and brain GHS-R1a levels [421, 602, 603]. Further
investigations are needed in this meritorious area.
5.12. Ghrelin in Pregnancy and Lactation. Ghrelin is
expressed abundantly by the placenta [604], and ghrelin
can stimulate GH release by human fetal pituitary cells in
vitro[605].Immunoneutralizationofmaternalghrelininthe
rat diminishes fetal body weight, raising the possibility of
maternal-fetal exchange of ghrelin [606]. Maternal ghrelin
and placentally derived variant-GH concentrations in the
h u m a npe a ka ta b o u t1 8a n d3 4w e e k sg e s t a t i o n ,r e s pe ct i v e l y ,
fall thereafter, and reach a nadir approximately 3 days
postpartum [607–609]. The decline in ghrelin in the third
trimester of pregnancy is inversely related to blood pressure,
resistin, and TNF-alpha levels [95, 610]. Although human
umbilical-cord acylghrelin levels exceed those in the mother,
theroleofplacentalghrelinisnotwellunderstood[611].Pla-
cental insuﬃciency, low birth weight, and maternal fasting
elevate fetal ghrelin levels [611, 612]. Postpartum acylghrelin
concentrations increase by several-fold over midpregnancy
values [613] ,b u tG Hr e s p o n s e st oG H Sa r er e d u c e di n
breastfeeding women, especially in the hyperprolactinemic
setting [614]. The basis may involve pregnancy-associated
suppression of hypothalamic GHRH and GHS-R1a with
reciprocal induction of the SS gene due to feedback by
high placental somatomammotropin (GH isotype V) and
maternal IGF-I concentrations [422].
In the rat, lactation induces both hypothalamic and pitu-
itary GHS receptors [615]. Pituitary GHS-R1a is maximal
in the newborn pup and pubertal animal [423]: Table 7.
Estradiol, T4, and GHRH may contribute to these maxima,
since the GHS-R1a promoter is responsive to estrogen and
cyclic AMP [122, 187]. Ghrelin is secreted into colostrum
and milk, but its eﬀect on the suckling infant is not
well delineated [616]. In one preclinical study, treating rat
pups with ghrelin reduced pancreatic exocrine development
before weaning and exerted the opposite eﬀect after weaning
[617].
5.13. Antireproductive Eﬀects of GHS. Exogenous ghrelin
reduces LH pulse frequency in the adult male rat, cyclic
or gonadectomized female rat, and ovariectomized monkey
[618–622]. Ghrelin may also inhibit embryo development,
decrease litter size, and delay pubertal onset in the male
rat [623, 624]. The mechanism may involve neuropeptide
Y (Y1 or Y5) or CRH-dependent inhibition of kisspeptin,
which together supervise gonadotropin-releasing hormone
secretion, and thereby pulsatile LH secretion [622, 624–627].
Other sites of inhibition may include uterine epithelium
(by inducing IGFBP-1 and lowering free IGF-I), Leydig
cells in the testis, and granulosa-luteal cells in the ovary
(by blocking steroidogenesis) [624, 628–633]. Although
physiological eﬀects are not clear, ghrelin is expressed in
sheep oocytes [634], and GHS-R1a in Sertoli (nurse) cells
in spermatogenic tubules [623]. Further study is required to
verify these inferences and evaluate clinical relevance [623].
For example, ghrelin infusion had no demonstrable eﬀects
on LH secretion in the early follicular phase of the menstrual
cycle [635].
5.14. Neuroendocrine Tumors. Both ghrelin and obestatin
are detected in various neoplasms, such as enterochromaﬃn
tumors (e.g., carcinoids), pituitary adenomas, and carci-
noma of the pancreas, lung, and breast [406, 636, 637]. The
amount of peptide secreted is usually insuﬃcient to serve as
a tumor marker or to elicit clinical symptoms or signs.
5.15. Body-Composition Eﬀects. Clinical studies in older
individuals indicate that prolonged (up to 1 year) adminis-
tration of GHS orally can increase lean-body mass, decrease
abdominal visceral fat, and possibly improve certain perfor-
mance measures, such as stair climbing and timed walking
[548, 638]. In analyses comprising 1-to-30 days of parenteral
GHS delivery, IGF-I concentrations also rise, but cortisol
and prolactin do not [270–272]: Figure 8. Adverse events
included insomnia, fatigue, small increases in fasting glucose16 International Journal of Peptides
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Figure 8:Continuoussubcutaneous(SC)infusionofsaline,GHRH
or ghrelin, or both (1μg/kg/hour) for 24 hours in a normal 69-
year-old woman. Data are 20-minutes GH concentrations (y-axis)
plotted against time (x-axis). AUC: area under the GH versus time
curve. IGF-I concentrations at the startand end of each infusion are
stated in the upper-right corner of each panel in units ofμg/L.
or glycated hemoglobin, and mild insulin resistance [638].
An important consideration is that acute diabetogenic eﬀects
of GHS may be attenuated by its longterm antidiabetic
eﬀects: Table 8. Insomnia could reﬂect GHS’s stimulation of
orexin pathways, whereas glucose intolerance could reﬂect
insulinostasis and insulin resistance due to acute free fatty-
acid release in humans [306]. Short-term use of ghrelin in
severe cachexia enhanced appetite and/or weight gain in
some studies [298, 300]. Whereas both glucocorticoid deﬁ-
ciencyandexcessinchronicdiseasescanreduceGHresponse
to GHS [4, 421], combined GHRH and ghrelin infusion is
more eﬀective at driving GH secretion than ghrelin alone
[270]: Figure 8. Viral vector delivery of ghrelin augmented
weight in the rat [639], introducing an additional potential
avenueoftreatmentbeyondsubcutaneous,intravenous,oral,
or intranasal administration [282].
A small percentage of GH-deﬁcient adults (10%) also
respond acutely to GHS, suggesting some preservation of
somatotrope function and GHRH availability [640]. In other
settings, injected GHS showed high speciﬁcity (95%) but
low sensitivity (80%) in detecting GH deﬁciency [641].
Combining GHS with GHRH and/or L-arginine improves
test sensitivity [4, 163].
5.16. Species Diﬀerences. Species diﬀerences in ghrelin struc-
ture, and to a lesser degree ghrelin action, have been
articulated [2, 26, 62, 276, 315, 642]. In the eel, ghrelin-21
predominates instead of ghrelin-28 [643]. In ﬁsh, decanoyl
Table 8: Diabetogenic and antidiabetogenic actions of ghrelin.
Prodiabetic eﬀects Antidiabetic eﬀects
stimulation of hepatic glucose
output chronic ↑ GH (lipolysis)
adipogenesis∗ increase lean-body mass
(chronic)
inhibition of insulin secretion decrease oxygen consumption
appetite enhancement increase uncoupling protein-1
acute free-fatty acid release∗
(human)
Antithermogenesis
decreased sympathetic
outﬂow
∗reduces tissue insulin action.
See Tables 3 and 6 for selected references.
rather than octanoyl ghrelin stimulates food consumption
and increases liver and fat mass [644].
5.17. Genetic Considerations. Epidemiological studies have
not identiﬁed common genetic haplotypes of GHS-R1a,
whichpredisposetoobesityorshortstature[645].Two-weak
associations of GHS-R1a polymorphisms with metabolic
syndrome or cardiovascular risk require conﬁrmation [646,
647]. Similar preliminary data apply to polymorphisms of
the ghrelin gene [393, 648].
6. Summary
In addition to increasing GH, as the term ghrelin implies,
GHS regulates inﬂammation, cellular proliferation, apop-
tosis, diﬀerentiation, and hormone secretion via receptors
located in the brain, stomach, intestine, heart, arterial wall,
bone, fat cells, and pancreas (exocrine and endocrine).
Acylated and unacylated ghrelin can exert both similar
(antiapoptotic) and opposite (appetitive) eﬀects. Promising
clinical applications of ghrelin agonists and antagonists
arise in relation to metabolic, gastric, GH-stimulating, anti-
inﬂammatory, and cardiotropic eﬀects. Nonetheless, there
are both desirable and potentially undesirable aspects of
chronic administration of ghrelin agonists or antagonists:
Table 9. Accordingly, substantial further advances in ghrelin
biology will be important.
7.Speculations
A saga is evolving within the ghrelin system due to
the recent identiﬁcation of the ghrelin O-acyl transferase
(GOAT) enzyme [47, 48]. The octanoyl addition is of major
biochemical and functional signiﬁcance. Not only is ghrelin
the ﬁrst natural hormone with a fatty-acid addition, but
also octanoylation is essential for binding and activating
the receptor, GHS-R1a, probably by determining the active
receptor-speciﬁc conformation of the ghrelin 1–28 molecule.
Final isolation of the GOAT enzyme may not be so easy, sinceInternational Journal of Peptides 17
Table 9: Issues concerning longterm administration of ghrelin
antagonists.
Desirable
↓ hyperglycemia
↑ insulin secretion
↓ appetite and food intake
↑ fat oxidation
↑ LH secretion?
Undesirable
↓ gastric emptying
↑ blood pressure (vasoconstrict)
↑ cardiac oxygen consumption?
↓ neoplastic apoptosis?
↑ inﬂammatory mediators?
↓ bone growth?
↑ gastric alkalinity and mucosal permeability?
↓ GH secretion (female)?
↓ neurogenesis (brainstem, cortex)?
↑ hypoglycemia during prolonged fast?
it is tightly bound by 12 transmembrane domains spanning
the endoplasmic reticulum (ER) [47].
Important issues arise regarding the chemistry and biol-
ogy of posttranslational octanoylation of ghrelin hormone.
The current concept is that preproghrelin 1–117 or proghre-
lin 1–94 is octanoylated for fundamental biological reasons.
In consonance with this postulate, production of octanoy-
lated ghrelin 1–28 is restricted to the conjoint anatomical
and intracellular sites of GOAT and preproghrelin 1–117
biosynthesis. Furthermore, if the desacylated ghrelin 1–28
is not directly octanoylated by GOAT, the speciﬁcity of
biological regulation is made even more precise. Available
evidence indirectly suggests that GOAT ﬁrst octanoylates the
preproghrelin 1–117 or the proghrelin 1–94 molecule. In
the former case, octanoylation would occur cotranslationally
rather than posttranslationally. This would require an inte-
grated cleavage of the signal peptide. Subsequently, several
prohormone convertases (PC1/3, PC2, and furin) permit
sequential formation of octanoylated Ser3 proghrelin 1–94
and octanoylated Ser3 ghrelin 1–28 [496, 649, 650].
Before the identiﬁcation of GOAT, Zhu, Cao, Voogd,
and Steiner published the ﬁnding that 1–94 proghrelin
was octanoylated, whereas ghrelin 1–28 remained unoc-
tanoylated [496]. These results support the inference that
octanoylated Ser3 ghrelin 1–28 is derived from octanoylated
proghrelin 1–94. The speciﬁc actions of convertases are now
being resolved. Zhu et al. demonstrated that PC1 must be
the enzyme that cleaves proghrelin in vivo, because only
proghrelin and not processed ghrelin is made in PC1-
knockoutmice[496].Inaddition,furincancleaveproghrelin
in vitro as described in the laboratory of Lindberg and, more
recently,thatofKojimaintransfectionstudies[72,649].Why
furin does not suﬃce in the PC1 gene-deletion model is not
clear.
In addition to GOAT, another human ER oxyesterase
has been puriﬁed and characterized from a stable human
erythroleukemia cell line by Ozawa, Speaker, and Lindberg
[56]. The acronym of this additional oxyesterase is ERAT
for endoplasmic reticulum O-acyl transferase. ERAT will
esterifymodiﬁed proghrelin having anN-terminal tripeptide
extension, but not the proghrelin 1–94 molecule. Notably
ERAT octanoylation is limited to the Ser2 amino-acid
residue, while Ser3,S e r 6,o rS e r 18 of ghrelin 1–28 are not
octanoylated. In addition, ERAT may transfer an array
of long-chain natural fatty acids, not just octanoic, to
as yet unknown substrates as well as to ghrelin 1–28,
when the latter contains an N-terminal tripeptide extension.
This speciﬁcity is reminiscent of N-myristoyltransferase.
Furthermore, ERAT is a soluble enzyme, but ﬁrmly bound
to the ER membrane, whereas GOAT is an insoluble integral
ER membrane-spanning enzyme. If ERAT and GOAT were
colocalized in the human stomach, one could envision
both independent and interdependent roles of ERAT and
GOAT. Although mammalian GOAT was initially considered
to only add octanoic or decanoic fatty acids to Ser3,
the laboratory of Kojima reported that GOAT eﬀectively
acylates truncated ghrelin peptides with n-hexanoic acid
in cultured cells [134]. ERAT might interact by limiting
in situ availability of octanoic acid to GOAT. A signiﬁcant
analytical point is that Ser2 versus Ser3 octanoylated ghrelin
would not be distinguishable by mass spectrometry, HPLC,
or probably immunologically, requiring instead mutagenesis
studies, amino-acid sequencing, binding, and biological
activity studies.
Whether ERAT acylates proghrelin in vivo is not known.
Albeit low in potency, Ser2,3 dioctanoylated ghrelin 1–28
can release GH in vivo in rats [125]. In addition, scien-
tists at Merck laboratories demonstrated that Ser2 mono-
octanoylated ghrelin 1–28 binds to GHS-R1a in vitro. Since
octanoylated ghrelin 1–28 may exert endproduct repression
of GOAT acyltransferase activity and since binding sites for
GOAT, ERAT, and GHS-R1a may overlap, small amounts
of Ser2 or Ser2,3 octanoylated ghrelin 1–28 might have
GOAT inhibitory activity. The proposition would be that
endogenous ERAT-derived ghrelin peptides may act on
GOAT only at intracellular sites.
Notable are two ghrelin deacylation enzymes, plasma
paraoxanase and gastric lysophospholipase I [156, 651].
Plasma paraoxanase is bound to high-density lipoproteins
and may especially determine physiological plasma ghrelin
levels. An interesting question is whether a major role
of blood-borne paroxanase is to minimize the actions
of octanoylated ghrelin or to maximize the actions of
desacylated ghrelin. On the other hand, gastric lysophos-
pholipase I may primarily regulate tissue ghrelin bioactivity
and subsequent vagal-aﬀerent activity as a function of the
amount and type of oral fatty-acid intake. In this regard, oral
octanoate increases, but oral dodecanoate decreases, plasma
octanoylated ghrelin levels [134]. Accordingly, the activity of
the two deacylases could be a function of amount and type
of substrate as well as factors that modify synthesis of and
catalysis by paroxanase and lysophospholipase I.18 International Journal of Peptides
The multiple inﬂuences of the ghrelin system depend
upon local and systemic posttranslational regulatory mech-
anisms and pleiotropic receptor-signaling in diverse target
tissues [518]. Moreover, gastric ghrelin is subject to food-
entrainable and circadian-clock inputs [652]. There is an
additional possibility that partial overlap of ghrelin-binding
properties of GHS-R1a, GOAT, and ERAT could contribute
to diﬀerences and similarities between ghrelin and GHS
mimetics as well as competition between full and partial
GHS-R1a agonists [653]. Brown and Goldstein demon-
strated that truncated ghrelin peptide analogs inhibit activity
of GOAT in vitro [46]. They proposed that native octanoyl
ghrelin 1–28 in higher concentrations may also inhibit
GOAT. If so, one could envision that certain GHS mimetics
might decrease or increase the activity of GOAT and ERAT
as well as that of GHS-R1a. For example, at a low dosage
Dap3 octanoylated ghrelin 1–28 inhibits octanoyl transferase
activity in vitro indicating that GOAT is a signiﬁcant site
of action, whereas this analog stimulates both GH release
and food intake in vivo, thus deﬁning a GHS-R1a (ghrelin
r e c e p t o r )s i t eo fa c t i o n[ 46, 654]. To assess the biochemistry,
physiology, endocrinology, and therapeutic implications of
peptide/non-peptide GHS mimetics and ghrelin will require
combined in vitro and in vivo structure-function and dose-
response analyses.
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